Bristol Myers Squibb closes immuno-oncology, cell therapy-focused Redwood City site

One of Chris Boerner’s first tours as the new CEO of Bristol Myers Squibb was of a 256,000 square-foot research facility in the Bay Area concentrated on the tumor microenvironment.

But months later, that Redwood City site is closing as part of a much-wider $1.5 billion-dollar restructuring effort. BMS is consolidating the work at a nearby site in Brisbane less than 20 miles away, according to a spokesperson Friday.